Obstet Gynecol Sci.  2016 Nov;59(6):498-505. 10.5468/ogs.2016.59.6.498.

Association between serum gonadotropin level and insulin resistance-related parameters in Korean women with polycystic ovary syndrome

• Park CH
• Chun S

• KMID: 2378574
• DOI: http://doi.org/10.5468/ogs.2016.59.6.498

Abstract

OBJECTIVE
To evaluate the relationship between serum gonadotropin level and parameters related to insulin resistance in Korean women with polycystic ovary syndrome (PCOS).
METHODS
This retrospective study included 138 women aged 18 to 35 years who were newly diagnosed with PCOS according to the Rotterdam consensus. Participants were divided into three groups based on the serum luteinizing hormone to follicle-stimulating hormone (LH/FSH) ratio in the early follicular phase: group 1 (LH/FSH <1), group 2 (1.0≤ LH/FSH >2.0), and group 3 (LH/FSH ≥2.0). The correlations between the LH/FSH ratio and various metabolic parameters were evaluated using Pearson correlation coefficients.
RESULTS
Patients with higher LH/FSH ratios showed higher total antral follicle counts and higher total ovarian volume. In the comparison of anthropometric and biochemical parameters among the three groups, the waist to hip ratio was the only parameter that differed significantly among the groups (P=0.003). Correlation analysis revealed no significant correlations between serum LH/FSH ratios and biochemical parameters related to insulin resistance. However, after adjustments for age and body mass index, a significant correlation between total cholesterol level and serum LH/FSH ratio was observed (r=0.221, P=0.018).
CONCLUSION
Most parameters related to insulin resistance, with the exception of total cholesterol level, are unrelated to the inappropriate pattern of serum gonadotropin secretion in Korean women with PCOS.

Keyword

Follicle stimulating hormone; Gonadotropins; Insulin resistance; Luteinizing hormone; Polycystic ovary syndrome

MeSH Terms

Body Mass Index
Cholesterol
Consensus
Female
Follicle Stimulating Hormone
Follicular Phase
Gonadotropins*
Humans
Insulin Resistance
Insulin*
Luteinizing Hormone
Polycystic Ovary Syndrome*
Retrospective Studies
Waist-Hip Ratio
Cholesterol
Follicle Stimulating Hormone
Gonadotropins
Insulin
Luteinizing Hormone

Reference

1. Kuzbari O, Doralis J, Peterson CM. Endocrine disorders. In : Berek JS, Novak E, editors. Berek & Novak’s gynecology. 15th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2012. p. 1075–1080.

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81:19–25.

3. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999; 84:1897–1899.

4. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2011. p. 501–518.

5. Lee JR, Kim SH. Anti-Mullerian hormone and female reproduction. Korean J Obstet Gynecol. 2009; 52:285–300.

6. Hsu MI, Liou TH, Liang SJ, Su HW, Wu CH, Hsu CS. Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertil Steril. 2009; 91:1168–1174.

7. Kubota T. Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. Reprod Med Biol. 2013; 12:71–77.

8. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352:1223–1236.

9. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004; 82:661–665.

10. Lin JF, Li X, Zhu MW. Exploration of the classification of polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi. 2006; 41:684–688.

11. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod. 2008; 23:1924–1931.

12. de Kat AC, Broekmans FJ, Laven JS, van der Schouw YT. Anti-Mullerian hormone as a marker of ovarian reserve in relation to cardio-metabolic health: a narrative review. Maturitas. 2015; 80:251–257.

13. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004; 82:970–972.

14. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009; 24:2917–2923.

15. Chun S. 1-h postprandial glucose level is related to the serum anti-Mullerian hormone level in women with polycystic ovary syndrome. Gynecol Endocrinol. 2015; 31:815–818.

16. Shim AR, Hwang YI, Lim KJ, Choi YM, Jeon YE, Seo SK, et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: the relationship with clinical, hormonal and metabolic characteristics. Korean J Obstet Gynecol. 2011; 54:659–665.

17. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab. 1997; 82:3728–3733.

18. Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod. 2011; 26:214–220.

19. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988; 66:165–172.

20. Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem. 2006; 43(Pt 3):217–219.

21. Minakami H, Abe N, Oka N, Kimura K, Tamura T, Tamada T. Prolactin release in polycystic ovarian syndrome. Endocrinol Jpn. 1988; 35:303–310.

22. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod. 2001; 16:2263–2266.

23. Wiser A, Shehata F, Holzer H, Hyman JH, Shalom-Paz E, Son WY, et al. Effect of high LH/FSH ratio on women with polycystic ovary syndrome undergoing in vitro maturation treatment. J Reprod Med. 2013; 58:219–223.

24. Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Mullerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med. 2014; 41:86–91.

25. Sikka P, Gainder S, Dhaliwal LK, Bagga R, Sialy R, Sahdev S. Ultrasonography of the ovaries and its correlation with clinical and endocrine parameters in infertile women with PCOS. Int J Fertil Womens Med. 2007; 52:41–47.

26. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005; 152:389–394.

27. Kurioka H, Takahashi K, Miyazaki K. Glucose intolerance in Japanese patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2007; 275:169–173.

28. Banaszewska B, Spaczynski RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Bialymst. 2003; 48:131–134.

29. Patel K, Coffler MS, Dahan MH, Yoo RY, Lawson MA, Malcom PJ, et al. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab. 2003; 88:5456–5461.

30. American Diabetes Association. Postprandial blood glucose. American Diabetes Association. Diabetes Care. 2001; 24:775–778.

31. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care. 2007; 30:1544–1548.

32. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care. 2009; 32:281–286.

33. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes. 2005; 54:1914–1925.

34. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab. 2002; 87:144–147.